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Abstract
Background: Mycobacterium-induced granulomas are the interface between bacteria and host immune response. During
acute infection dendritic cells (DCs) are critical for mycobacterial dissemination and activation of protective T cells. However,
their role during chronic infection in the granuloma is poorly understood.
Methodology/Principal Findings: We report that an inflammatory subset of murine DCs are present in granulomas induced
by Mycobacteria bovis strain Bacillus Calmette-guerin (BCG), and both their location in granulomas and costimulatory
molecule expression changes throughout infection. By flow cytometric analysis, we found that CD11c+ cells in chronic
granulomas had lower expression of MHCII and co-stimulatory molecules CD40, CD80 and CD86, and higher expression of
inhibitory molecules PD-L1 and PD-L2 compared to CD11c+ cells from acute granulomas. As a consequence of their
phenotype, CD11c+ cells from chronic lesions were unable to support the reactivation of newly-recruited, antigen 85B-
specific CD4+IFNc+ T cells or induce an IFNc response from naı¨ve T cells in vivo and ex vivo. The mechanism of this inhibition
involves the PD-1:PD-L signaling pathway, as ex vivo blockade of PD-L1 and PD-L2 restored the ability of isolated CD11c+
cells from chronic lesions to stimulate a protective IFNc T cell response.
Conclusions/Significance: Our data suggest that DCs in chronic lesions may facilitate latent infection by down-regulating
protective T cell responses, ultimately acting as a shield that promotes mycobacterium survival. This DC shield may explain
why mycobacteria are adapted for long-term survival in granulomatous lesions.
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Introduction
The formation of a granuloma in response to a pathogen creates
an immunological foci that contains the antigen. During infection
with mycobacteria, the granuloma contains the bacteria, prevents
dissemination, and localizes immune responses to limit tissue
damage. Though it protects the host, the granuloma also facilitates
bacterial survival, which may eventually allow for disease
tansmission. Acute mycobacteria-induced granulomas formed
early in infection are large lesions with high bacterial burden
[1]. They are characterized by the presence of a high proportion
of IFNc-producing CD4+ T cells, which are critical activators of
microbicidal pathways in bacteria-containing macrophages [2].
Chronic granulomas are smaller, more structured lesions with a
lower bacterial load and reduced killing–they contain bacteria and
prevent dissemination, but are ultimately unable to sterilize the
lesion. In this way the chronic granuloma provides a home for
bacterial latency, in which reactivation can occur decades later
after immune stress from AIDS, old age, or anti-TNFa therapy,
for instance. Reactivated bacteria grow, disseminate and often
result in fatality [3,4]. Mutant mycobacteria strains that induce
poor granuloma formation result in increased bacterial growth
[5–9]. Virulent mycobacteria species have actually evolved gene-
specific strategies to promote early granuloma formation and
ensure their own long-term survival so as to increase chances of
disease transmission. While the function of acute granulomas is the
focus of intense research, much less is known about chronic
granulomas.
DCs are critical in the initiation of immune responses since they
are the only antigen presenting cell capable of activating naı¨ve T
cells and efficiently initiating a recall T cell response [10].
Following mycobacterial infection, DCs are required for initiation
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of the adaptive immune response by facilitating dissemination of
mycobacteria and mycobacterial antigen from the site of infection
to the draining lymph node [11–15]. However, little is known
about the role of DCs during chronic infection. Immunohisto-
chemistry of chronic granulomas from lungs of tuberculosis
patients shows DCs in and around the granuloma [16](unpublished
data). To track and analyze DCs in sarcoid granulomas, the likely
sites for long-term mycobacterial persistence, we used a systemic
Mycobacterium bovis Bacillius Calmette-guerin (BCG) infection
model. This model offers several advantages in the study of latent
mycobacterial infections. Lesions from BCG infection are the best
characterized of any mycobacterial-induced granulomas models,
are technically convenient and numerous to isolate, and very
recently have been studied with new and intriguing in vivo imaging
[17]. Most of the two billion people infected with Mycobacterium
species control infection by maintaining symptom-free latency of
the bacilli in chronic granulomas. Murine infection with
Mycobacterium tuberculosis results in a sustained and eventually fatal
bacterial burden, which does not reflect the low bacterial burden
found in chronically infected humans [18,19]. Murine infection
with BCG, however does achieve the low bacterial load observed
during human Mtb infection. Furthermore, three billion people
have been vaccinated with live BCG, which has been proposed to
survive within granulomas, with 100 million people newly
vaccinated each year, yet its efficacy remains limited [20–22].
The ineffectiveness of the most widely distributed vaccine
worldwide certainly warrants rigorous investigation.
In addition, Mycobacterium bovis also presents serious health
threats of its own. An estimated 1–2% of human tuberculosis cases
are caused by Mycobacterium bovis in developed countires, while in
still developing countries it is 10%, totaling 20–200 million cases
worldwide [23–25]. With increased immigration into the U.S.
from Mexico, this presents a more imminent threat to the U.S.,
especially in binational border communities [26]. Primarily
acquired zoonotically by the consumption of raw meat and
unpasteurized milk from infected bovine, there have also been
cases of Mycobacterium bovis transmission from person to person
[25,27,28]. M. bovis tuberculosis patients are over twice as likely to
die during treatment compared to those with Mycobacterium
tuberculosis, which may be attributed to its universal resistance to
the first line tuberculosis drug pyrazinamide [26].
Here, we report data that suggests DCs are critical in the
transition from the acute to chronic granulomas. CD11c+ cells
from acute and chronic granulomas differ in co-stimulatory
phenotype, location within the granuloma, and most importantly,
capacity to support an IFNc-recall response from newly-recruited,
mycobacteria-specific CD4+ T cells in the granuloma and generate
an IFNc response from naı¨ve CD4+ T cells ex vivo. Our data
suggests that CD11c+ cells in chronic granulomas shield the
bacteria locally from IFNc-producing CD4+ T cells and that this
mechanism involves the PD-1:PD-L signaling pathway. This
protective shield provided by local CD11c+ cells may have
contributed to the evolutionary adaptation of other infectious
agents to survive within granulomatous lesions.
Results
Inflammatory DCs are recruited into both acute and
chronic mycobacterium-induced granulomas
Though there is an ever-growing appreciation of DCs’ ability to
bridge innate and adaptive immunity, little is still known about
their role in chronic infection. At three, six and ten weeks after
infection with BCG, granuloma-infiltrating cells were isolated
from liver as previously described [29], and an isolated granuloma
cell suspension was generated from 3–7 pooled mice per time
point. Phenotypic analysis by flow cytometry revealed the presence
of a CD11c+ population in both acute and chronic granulomas
(Fig. 1A). Notably, the proportion of CD11c+ cells was similar in
both three-week (acute) and ten-week (chronic) lesions. Analysis of
the CD11c+ population showed that the predominant population
in both acute and chronic lesions was the monocyte-derived
‘‘inflammatory’’ DC subset, characterized by CD11cint-hiCD11b-
hiGR-1+ (Fig. 1B) [30,31]. The differentiation of this population
from recruited blood-derived monocytes into inflamed tissue is
well described. The frequency of this DC population within the
granuloma was relatively consistent throughout infection, as
measured by their gated percentage of total granulomas cells.
When the absolute number of CD11c+cells per gram of liver tissue
was determined, the significant majority of CD11c+ cells were
present at six weeks after infection (Fig. 1C). The decreased
number of CD11c+ cells per gram of liver tissue observed at ten
weeks is likely due to the decline in both bacterial burden and
subsequent number of lesions observed during chronic time points.
Overall, these data demonstrate the presence of a DC-like
population of cells in both acute and chronic mycobacterium-
induced granulomas.
Location of CD11c+ cells in granulomas changes with
progression from acute to chronic infection
The granuloma is a microenvironment with complexity in
architecture and cellular distribution. Different locations within
the granuloma represent diverse immunological niches for optimal
interactions between antigen presenting cells, T and B cells,
cytokines, and chemokines [32,33]. As critical immune modula-
tors, we expect the phenotype of DCs and their location in the
granuloma to be important components of their function and
interaction with other immune cells. To locate DCs in granulo-
mas, liver from mice systemically infected with BCG was frozen
and examined by immunofluorescent microscopy with anti-
CD11c staining three, six and ten weeks after infection. We
classified DC location in the granuloma based on three
generalized areas: the center, the lymphoid cuff of cells forming
the periphery, or outside in extra-granulomatous tissue (Fig. 2A).
We observed differential CD11c+ cellular location throughout
infection. Most CD11c+ cells in three-week granulomas were
located in the lymphoid cuff, but as infection progressed the
majority were distributed near the center of the granuloma
(Fig. 2B), a common location for bacteria during chronic infection.
Interestingly, CD11c+ cells from ten-week granulomas were
distributed more evenly in all locations. We confirmed these
findings using CD11c enhanced yellow fluorescent protein
(CD11c-EYFP) mice with ubiquitously fluorescing DCs [34],
infected with BCG -liver was analyzed by microscopy three, six
and ten weeks later (Fig. 2C). Using both anti-CD11c antibody
staining on tissue from WT mice and transgenic CD11c-EYFP
mice, we show that this cellular subset is differently located
throughout the course of infection.
A portion of CD11c+ cells are infected with mycobacteria
in both acute and chronic granulomas
Previous studies have shown that both resident and recruited
DCs take up live bacilli, where they can persist for at least two
weeks after infection [12]. Though mycobacteria infect both
macrophages and DCs, activated DCs lack the ability to kill
intracellular bacilli as effectively [35]. Thus, granuloma DCs may
provide a long-term reservoir for bacteria during chronic infection.
To investigate this possibility, we analyzed three- and ten-week
Dendritic Cells in Granulomas
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granulomas from CD11c-EYFP mice infected with dsRED BCG
(Fig. 3A). In both acute and chronic granulomas some BCG was
located in CD11c-EYFP+ cells, detected by red rods located in
homogenous green cytoplasmic fluorescence. Although the
expected majority of bacteria were in macrophage-like cells
(CD11c-EYFP2), there was significantly more BCG per cell in
those CD11c-EYFP+ cells that were infected compared to than
non-DCs (CD11c-EYFP2) both in acute and chronic lesions
(Fig. 3A Right). Flow cytometric analysis of granuloma CD11b+
and CD11c+ cells from mice systemically infected with GFP-BCG
further confirmed that both DC-like cells (CD11c+) and macro-
phage-like cells (CD11c2CD11b+) are infected at acute and
chronic time points (Fig. 3B). Although the CD11c2CD11b+ cell
population had a higher frequency of GFP BCG-infected cells at
10 weeks (8.61% compared to 1.17% of CD11c+ cells) (Fig. 3B),
the 1.17% of CD11c+ cells infected had a higher GFP fluorescence
intensity than CD11c2CD11b+ cells, 28.7% compared to 17.3%,
respectively (Fig. 3C). The higher frequency of GFP intensity
indicates more GFP+ bacilli per cell. These data suggest that while
macrophage-like cells (CD11c2CD11b+) are more frequently
infected, DC-like cells (CD11c+), when infected, contain more
bacteria per cell.
CD11c+ cells in chronic granulomas display decreased
expression of MHCII and T cell co-stimulatory molecules,
and increased expression of inhibitory molecules
DCs are equipped with an array of receptors that facilitate T
cell activation. To investigate the phenotype of DCs in granulomas
throughout infection, wild-type mice were infected with BCG and
Figure 1. Inflammatory DCs present in both acute and chronic mycobacterium-induced granulomas. C57BL/6 mice were systemically
infected intraperitoneally with BCG. Three, six and ten weeks post infection livers were harvested, and granuloma-infiltrating cells were isolated. A,
FACS analysis of CD11c and CD11b populations in liver granulomas. Plot obtained from gate of SSC high FSC high population, excluding
lymphocytes. B, Phenotypic analysis of CD11c+ cells from gating shown in A. Graph shows absolute number of cells per gram of liver tissue of cells
positive for designated DC subsets listed below graph. C, Absolute number of CD11c+ cells per gram of tissue, population obtained from gate shown
in A. Statistical differences among groups shown on graph. FACS plots and graphs generated from 3–7 mice pooled per time point for granuloma
preparation and representative of three independent experiments.
doi:10.1371/journal.pone.0011453.g001
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granuloma-infiltrating cells were isolated at three, six and ten
weeks after infection. Granuloma cells were stained with
antibodies against MHCII, costimulatory (CD40, CD80 and
CD86) and inhibitory (PD-L1 and PD-L2) surface molecules and
analyzed by flow cytometry (Fig. 4A). After gating on CD11c+ cells
(Fig. 1A), we observed a distinct change in phenotype of this
cellular subset from three weeks to ten weeks after infection.
Compared to naı¨ve splenic CD11c+ cells, CD11c+ cells from three-
week granulomas had high expression of MHCII, T cell
costimulatory molecules, CD40, CD80 and CD86, and low
expression of inhibitory molecules PD-L1 and PD-L2. Ten weeks
after infection these cells had lower expression of T cell
costimulatory molecules, and higher expression of both PD-L1
and PD-L2 (Fig. 4A Black arrows indicate directional shift of
MHCII and costimulatory molecule expression compared to
expression level observed 3 weeks after infection). MHCII and
costimulatory molecules CD40, CD80, and CD86 had an average
0.5 fold decrease in their MFI intensity from three to ten weeks
after infection (Fig. 4B). In contrast, PD-L1 and PD-L2 increased
in their mean MFI by 2 and 3.5 fold, respectively. These data
suggests that DC-like cells from early three-week granulomas
would support potent T cell activation (or re-activation), but those
from 10 week granulomas may not.
The majority of CD4+ cells maintain close contact with
CD11c-EYFP+ cells in both early and chronic granulomas
The differential expression of costimulatory and inhibitory
molecules on acute and chronic CD11c+ cells likely has
different consequences on T cell responsiveness in acute and
chronic granulomas. We have already shown that the location
of this cellular subset changes in the granuloma throughout
infection (Fig. 2). Next, we investigated if the differential
location of CD11c+ cells in acute and chronic granulomas
changed the frequency of contact between T cells. We
speculated that changes in DC phenotype would be less
relevant to T cell function if contact between the two cell
types was ablated by the altered DC location in the lesion. We
also speculated that any loss of contact between the two cell
types would result in an inability of DCs to re-stimulate newly
primed T cells recruited to granulomas. To address this
question, we quantitatively analyzed three- and ten-week
granulomas for CD4+:CD11c-EYFP+ cellular contact by
fluorescent immunohistochemistry (Fig. 5A and B). This was
done by staining liver sections from three- and ten-week
infected CD11c-EYFP mice with fluorochrome-labeled anti-
CD4, and analyzing all CD4+ cells per lesion. We observed
similar frequencies of CD4+:CD11c-EYFP+ cell contact be-
tween three- and ten-week granulomas, and importantly, found
that the statistically significant majority of CD4+ T cells from
both three- and ten-week granulomas were in contact with
CD11c+ cells. Under high magnification, co-localization of
CD11c-EYPF+ (DCs) and dsRed (CD4+ T cells) is easily seen
(Fig. 5B- 2nd and 4th column, 1st and 2nd row). The few CD4+ T
cells that were not in contact with CD11c+ cells may be due to
restrictions of the sectioned plane, such that contact with a
CD11c+ cell may be above or below the plane. These data
demonstrate that CD11c+ cells maintain physical contact with
CD4+ T cells in both acute and chronic granulomas.
Collectively, these data, in combination with the observed
phenotypic changes (Fig. 4), suggest that DC-like cells may have
direct effects on both resident and newly recruited mycobac-
terium-specific T cells during both early and chronic infection.
CD4+ T cells produce less IFNc in chronic compared to
acute granulomas
To test for differences between acute and chronic granuloma-
resident CD4+ T cell activity, granuloma cells from both lesions
were re-stimulated ex vivo after systemic infection with BCG. CD4+
T cells from ten-week granulomas showed a dramatic decrease in
both IFNc production and LFA-1 expression compared to three-
week granulomas (Fig. 6). In fact, the IFNc-producing T cell
population in ten-week granulomas fell below our detection level
in many samples. These observations, along with those detailing
an inhibitory phenotype of CD11c+ cells in chronic granulomas
suggests a suppressive DC population in chronic granulomas.
Since many current therapeutic efforts are aimed at generating an
increase in Mtb-specific IFNc-producing Th1 cells, we next tested
the ability of DCs to re-boost newly recruited CD4+ T cells in
acute and chronic granulomas.
Figure 2. Location of DCs in acute and chronic mycobacterium-
granulomas is different. A, Schematic outline of DCs in the center,
periphery or outside of the granuloma. B, Distribution of DC location
from stained sections. 42, 43 and 17 lesions combined from three mice
per time point were observed for CD11c+ location for three, six and ten
weeks, respectively. C, CD11c-EYFP mice were systemically infected
with dsRED BCG for three, six and ten weeks. EYFP expression (green
cells) and DAPI nuclear stain (blue). Granulomas are outlined with white
dashed lines and shown at 10006magnification.
doi:10.1371/journal.pone.0011453.g002
Dendritic Cells in Granulomas
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11453
APCs in chronic granulomas support lower reactivation
of newly recruited mycobacterium-specific IFNc-
producing CD4+ cells compared to acute granulomas
A recent study by Egen and colleagues demonstrated the
movement of T cells in granulomas, and in doing so, also
demonstrated their ability to interact with many local cells [17].
Additionally, newly primed T cells require a second antigen
encounter at the site of inflammation in order to rapidly secrete
cytokines [36]. Here, we tested the ability of granuloma-resident
APCs from three- and ten-week granulomas to induce IFNc
production from newly recruited mycobacterium-specific T cells
that migrated to pre-existing granulomas. For this, CD11c-
EYFP mice were infected with dsRED BCG followed three or
ten weeks later by adoptive transfer of CFSE-labeled, dsRED
CD4+ T cells specific for mycobacteria-secreted antigen 85B
(Fig. 7A). One day before adoptive transfer of Ag85B-specific T
cells, mice received subcutaneous footpad injections of GFP-
BCG to provide an immune boost. GFP-BCG was used for the
secondary systemic boost in order to distinguish between
previously established three and ten-week dsRED BCG-induced
granulomas in the liver. We expected this immune boost to
induce migration of adoptively transferred cells to the draining
popliteal lymph nodes and acquire a Th1 phenotype, mimicking
a therapeutic boost intended to generate a high systemic level of
mycobacterium-specific IFNc-producing CD4+ T cells. Six days
after adoptive transfer, cells from three- and ten-week
granulomas were isolated for ex vivo recall of IFNc production.
CD4+dsRED+ co-staining identified adoptively transferred 85B
antigen-specific TCR transgenic T cells. Analysis by flow
cytometry showed that the proportion of LFA-expressing,
adoptively transferred T cells that migrate into three- and ten-
week granulomas is similar, demonstrating that T cell recruit-
ment into chronic granulomas was not hindered (Fig. 7B).
Fluorescent microscopy confirmed the presence of newly
recruited Ag85B-specifc T cells into the granulomas and also
showed their proximity to CD11c-EYFP cells (Fig. 8B, lower
panel). Importantly, upon ex vivo stimulation, there was a lower
frequency of adoptively transferred Ag85-specific T cells in
chronic granulomas that were able to produce IFNc compared
to three-week granulomas (Fig. 7C individual FACS plots).
These data support the hypothesis that DC-like cells in chronic
lesions, which express high levels of inhibitory molecules,
suppress local IFNc production from newly recruited mycobac-
terium-specific T cells. These experiments are relevant because
Figure 3. A portion of BCG is sustained within CD11c+ cells, both in acute and chronic granulomas. A, Left, Fluorescent images of CD11c-
EYFP2 (left panels) and CD11c-EYFP+ cells (right panels) with dsRED BCG at three and ten weeks. Images magnified from 10006 images. DAPI nuclear
stain (blue), dsRED BCG (red rods) and cytoplasmic CD11c-EYFP cells (green). Right, Average number of viable dsRED BCG rods per cell type (CD11c-
EYFP+ or non-fluorescent) within the granuloma at three- and ten-weeks after infection. Data are represented as mean +/2 SEM, P,0.0001. B, FACS
plots generated from CD11c+ gate (left plot) and CD11b+CD11c2 gate (right plot). Boxed gate shows percentage of cells containing GFP-BCG. Gate
placement was made from non-fluorescent-BCG infected CD11b+ and CD11c+ cells, not shown. Plots representative of 3- and 10-week time points
with 3, 8 and 8 mice per group, respectively. C, Histograms generated from 10 week CD11c+ (1.17) and CD11b+CD11c2 (8.61) GFP BCG+ gates in (B).
doi:10.1371/journal.pone.0011453.g003
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they attempt to evaluate the potential effectiveness of current
vaccine and therapeutic efforts aimed at increasing the activity
and number of IFNc-producing CD4+ T cells. Therefore, these
data suggest that despite a high level of systemic mycobacteri-
um-specific IFNc-producing T cells, DCs may be shielding
bacteria within the granuloma environment from IFNc, a
critical component for controlling infection.
CD11c+ cells in chronic granulomas are less efficient at
inducing an IFNc-producing CD4+ T cell immune
response
Our data suggests that CD11c+CD11b+ cells in chronic
granulomas have an inhibitory phenotype (Fig. 4) and down
regulate systemic IFNc producing T cells after they home to
granulomatous lesions (Fig. 7). The fact that chronic granulomas
contain much less bacterial antigen might provide an alternative
explanation to the previous observation of limited IFNcproduc-
tion in chronic lesions. To test this possibility, CD11c+ cells were
purified from three- and ten- week granulomas and co-cultured
with purified, naı¨ve OT-II CD4+ T cells (Fig. 8A). Exogenous
OVA protein alone was added to cultures, 48 hours later cells
were analyzed for IFNc and IL-2 production by flow cytometry
(Fig. 8B). CD11c+ cells purified from three-week granulomas
were more efficient at inducing IFNc and IL-2 production from
OT-II CD4+ T-cells than CD11c+ cells from ten-week granulo-
mas. IFNc production was confirmed by ELISA after ex vivo
stimulation for 48 hours (Fig. 8B Right). These data show that
even though differential amounts of antigen in acute and chronic
granulomas may contribute to the decreased efficiency of
mycobacterium-specific T cells to produce IFNc, DCs from
acute and chronic granulomas have an inherent difference when
regulating local IFNc responses. Furthermore, these data
collectively suggest that an inhibitory population of CD11c+ cells
in chronic granulomas down-regulates the activity of IFNc-
producing CD4+ T-cells.
Blockade of PD-L:PD-1 signaling increases the ability of
CD11c+ cells in chronic granuloma to reactivate CD4+ T
cells ex vivo
Previous studies have demonstrated that blockade of the PD-
L:PD-1 pathway enhances T cell responses [37–40]. To determine
if increased PD-L expression shown on CD11c+ cells from chronic
granulomas (Fig. 4) had a direct effect on their inability to
stimulate CD4+ T cells activation (Fig. 7 and 8), we tested the
effect of CD11c+ PD-L- T cell PD-1 interaction on T cell
responses. CD11c+ cells were purified from three- and ten-week
granuloma preparations by magnetic separation and were
pretreated with media or isotype controls, 10 mg/mL of both
anti-PD-L1 and -PD-L2 mAbs, or 50 mg/mL of soluble PD1-Fc
that binds both PD-L1 and PD-L2 [41]. After 1 hour, purified
Ag85B-specific CD4+ T cells from lymph nodes of 3 week BCG-
infected P25 mice were added to the DCs at a ratio of 5:1
(CD4+:CD11c+). Protein transport inhibitor and 0.5 mg/mL
Ag85B peptide was added to each coculture, and intracellular
IFNc was measured after 4 hours for flow cytometry. Treatment
with anti-PD-L1 and -PD-L2 mAbs (Fig. 9A), and PD1-Fc (Fig. 9B)
significantly increased IFNc production from T cells stimulated by
CD11c+ cells from 10-week granuloma. Both PD-L blocking
treatments restored IFNc to production levels achieved by 3-week
CD11c+ cell stimulation. Collectively, these data suggest that DCs
in chronic granulomas actively inhibit antigen-specific T cell
responses in a way that facilitates chronic infection and survival of
Mycobacterium bovis.
Discussion
Here we report that a DC-like population, characterized by
CD11c+ expression, are present in acute and chronic BCG-
induced granulomas, but their location, phenotype, and ability to
induce IFNc responses distinctly changes throughout the course of
infection. CD11c+ cells in acute lesions are primarily located in the
Figure 4. Surface expression of activating and inhibitory costimulatory molecules and chemokine receptors is different on
CD11c+ cells in acute and chronic granulomas. CD11c+ cells from granuloma single cell suspensions obtained from three, six and ten week
systemically infected C57BL/6 mice were phenotyped using flow cytometry. A, Histograms represent fluorochrome surface staining with
monoclonal antibodies against MHCII, activating costimulatory molecules (CD40, CD80 and CD86) and inhibitory costimulatory molecules (PD-L1
and PD-L2). Black-dashed histograms represent costimulatory molecule expression on naı¨ve splenic CD11c+CD11b+ cells. Blacks arrows indicate
directional shift in MHCII and costimulatory molecule expression compared to 3-week expression levels at time points where substantial change is
observed. Histograms representative of 3 independent experiments with 3–7 mice per group. B, Average fold change between three and ten week
time points in mean fluorescent intensity of MHCII and costimulatory molecules. Average generated from fold change in three independent
experiments.
doi:10.1371/journal.pone.0011453.g004
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lymphoid cuff of the granuloma and have high expression of
MHCII and T cell stimulatory molecules CD40, CD80 and
CD86. However, those from chronic granulomas have low
expression of MHCII and co-stimulatory molecules, high
expression of T cell inhibitory molecules PD-L1 and PD-L2, and
also migrate toward the granuloma center. Most importantly,
CD11c+ cells from acute granulomas have a greater capacity to
induce IFNc production from CD4+ T-cells compared to those
from chronic granulomas. When PD-L expression on CD11c+
cells was blocked ex vivo, their ability to restimulate allogenic CD4+
T cells to produce IFNc was restored to the level observed during
acute infection. Although these data demonstrate a direct effect of
granuloma DCs on CD4+ T cell IFNc production ex vivo, they do
not rule out the possibility that other factors within the granuloma
may also influence IFNc production. This CD11c+ shield may
induce local tolerance within chronic granulomas, despite the high
systemic level of CD4+IFNc+ anti-mycobacterial T cells. The
ability of CD11c+ cells to shield mycobacteria from local IFNc T
cell responses may be one explanation for the ability of
mycobacteria to survive indefinitely in granulomas.
IFNc is critical for activation of mechanisms in macrophages
that kill engulfed bacteria –these include production of reactive
nitrogen and oxygen species, as well as stimulation of phagosome-
lysosome fusion [2]. The necessity of mycobacterium-specific
IFNc-producing CD4+ T cells for controlling mycobacterial
growth is demonstrated in mouse models with ablated CD4+ T-
cell responses, HIV infected individuals, and patients lacking
functional IFNc receptors, all of which are unable to control Mtb
infection [4,42–47]. While it seems rational that improved vaccine
strategies have aimed to increase CD4+ T-cell responses, the
results have unfortunately been ineffective at achieving bacterial
clearance [48,49]. Our work here detailing the presence of an
inhibitory DC-like population in chronic granulomas provides a
possible explanation for these failures.
PD-Ls have been shown to negatively regulate T cells by
inhibiting proliferation and cytokine production and are exploited
by several microorganisms to evade anti-microbial immunity
[50,51]. PD-L expression on antigen presenting cells is also key for
the generation of peripheral tolerance [52]. What drives the
transition of a population of DCs that stimulate T cells to one that
Figure 5. CD4+ T cells maintain contact with CD11c-EYFP+ cells in both acute and chronic granulomas. A, Quantitative analysis of CD4+ T
cell contact with CD11c-EYFP+ cells in granulomas from three- and ten-week liver sections. All CD4+ T cells per granuloma section were determined to
be in contact (green bars), or not in contact (white bars) with CD11c-EYFP+ cells. For each time point, liver sections from 3 independent mice were
used, and 10–15 lesions per section were analyzed. Data are represented as mean +/2 SEM, P,0.0001. B, Fluorescent images demonstrating CD11c-
EYFP contact with CD4+ cells. Granulomas are outlined with white dashed lines at 10006magnification and colors shown depict CD11c-EYFP (green
cells), anti-CD4 Alexa 647 (red cells), and DAPI nuclear stain (blue).
doi:10.1371/journal.pone.0011453.g005
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inhibits them is a key question. One possibility is that the
proinflammatory environment of acute granulomas provides
signals to drive increased expression of PD-L receptors on APCs.
IFNc itself, which is abundant in acute granulomas, up-regulates
PD-L on DCs [41,51,53–55]. To test potential IFNc regulation of
PD-L expression on DCs during BCG infection, we infected IFNc
KO mice, but observed no differences in PD-L expression
compared to wild-type mice six weeks after infection (data not
shown). However, this is likely due to compensatory effects of other
proinflammatory factors in the granuloma, such as TNFa, IL-6,
IL-1b, IL-4, GM-CSF, and/or TSLP, which have all been found
to induce an inhibitory DC phenotype [56,57]. In addition to host-
derived products, certain mycobacterial antigens have also been
shown to interfere with DC maturation and down-regulate the
ability of the DCs to induce Th1-IFNc responses from antigen-
specific T cells [58–61]. TLR 2 and 4 stimulation has been shown
to induce inhibitory and tolerogenic DCs, while PD-L up-
regulation results from TLR 7/8 stimulation [56,62].
In accordance with our finding that CD11c+ cells in human
Mtb-induced granulomas express PD-L1 and -2 (data not shown),
recent data by Juardo et al. shows that mycobacterial antigen-
induced expression of PD-1 on lymphocytes from patients with
tuberculosis interferes with anti-mycobacterial T cell effector
functions [40]. PD-L1 expression has also been shown in BCG-
induced bladder granulomas from patients receiving BCG therapy
for urothelial carcinoma of the bladder [63]. Together with our
own data, these human data suggest that once lymphocytes reach
Mtb-induced granulomas, PD-1: PD-L1/2 ligation may interfere
with effector T cell responses. A recent finding by Einarsdottir et
al. has shown that administration of anti-PD-1 and -PD-L1
blocking antibodies at the onset of chronic Mycobacterium tuberculosis
infection in mice does not effect CD8+ T cell function or bacterial
load four weeks later [71]. It is difficult to compare data from in
vivo and in vitro experiments, but one possible explanation for the
lack of response observed in vivo is that PD-L2 was not also
selectively blocked in their study. PD-L2 is more exclusively
expressed by DCs and can also ligate with PD-1, potentially
compensating for any blocking of PD-L1 [41].
DCs may also contribute to latency by acting as a long-term
reservoir for mycobacteria, ensuring their survival in highly
bactericidal environments like the granuloma. Not only does our
data show BCG-infected CD11c+ cells in acute and chronic
granulomas, but those CD11c+ cells infected often contained more
than one bacterium per cell. It has been reported that DCs are less
efficient at killing intracellular mycobacteria [35,64–66], though
altered compartmental trafficking of bacilli inside DCs prohibits
mycobacterial access to the necessary nutrients required for growth
[67,68]. These studies ultimately suggest two things. The first is that
while the majority of mycobacteria infect macrophages, a portion of
mycobacteria that infect DCs may avoid the effective killing
mechanisms of macrophages. The second is that mycobacterium
may infect DCs so that they can influence the immunosuppressive
effects of the PD-L1/2 system. Studies have shown that human
monocyte-derived DCs infected with either Mtb or BCG have
reduced expression of MHCII and CD80, produced IL-10 over IL-
12, and had an impaired ability to generate IFNc-secreting CD4+ T
cells [69–72]. Furthermore, a recent in vivo study by Wolf et al.
showed that the myeloid DC population responsible for shuttling
Mtb from the lungs to the draining lymph nodes in mice poorly
stimulated IFNc production from Ag85B-specific CD4+ T cells
[15]. While these data suggest that mycobacteria-infected DCs
induce immunosuppressive effects, a body of data actually suggests
the opposite. Upon infection of both murine and peripheral
monocyte-derived human DCs with either Mtb or BCG in vitro and
in vivo, DCs matured, produced Th1-promoting cytokines, and
induced IFNc-producing T cells [73–79]. This collection of
conflicting data may be the result of the various models used, but
taken together; the data collectively demonstrate the multi-
functionality of DCs during infection.
The scheme in Figure 10 summarizes our results, which
indicates a distinct change in CD11c+ cell phenotype and function
in bacteria-containing granulomas (Fig. 10). It is possible that DCs,
by affecting local IFNc availability, may contribute to granuloma
maturation and bacterial persistence. Future studies of DC
function in chronic Mtb-induced granulomas will be needed to
both extend our findings and develop vaccine strategies that would
weaken the shielding effect of DCs in chronic granulomas.
Materials and Methods
Mice
Wild type C57BL/6 (H2b) and IFNc-deficient mice were
purchased from the Jackson Laboratory (Bar Harbor, ME). CD11c-
EYFP transgenic mice on the C57BL/6 background were a generous
gift from Dr. Michel C. Nussenzweig (Rockefeller University, NY)
[34]. P25 transgenic mice on the Rag2/2 background were a
generous gift from Drs. Rothfuchs and Sher (NIH, Bethesda, MD).
P25 mice were bred with Actb-DsRED.T3 transgenic mice from the
Jackson Laboratory to obtain dsRED P25 mice.
Ethics Statement
Mice were housed and bred in microisolator cages in a
pathogen-free facility at the University of Wisconsin Animal Care
Unit (Madison, WI), and husbandry and experimental procedures
were performed according to the guidelines of the Institutional
Animal Care and Use Committee. All animal protocols were
approved by the University of Wisconsin Institutional Animal
Care and Use Committee. Animal protocol approval under
protocol M01616.
Infection
The Pasteur strain of BCG (Staten Serum Institute, Denmark),
kanamycin-resistant GFP-expressing BCG, or kanamycin-resistant
dsRED-expressing BCG were grown in Middlebrook 7H9
supplemented with 0.05% Tween 80 and 10% oleic acid-
dextrose-catalase supplement (Difco, Detroit, MI) in the presence
Figure 6. IFNc recall response of CD4+ T cells is much higher in
acute compared to chronic granulomas. Granuloma cells from
three- and ten-week systemic BCG infected animals were isolated and
stimulated ex vivo for five hours with anti-CD3. FACS plots show
intracellular IFNc staining and LFA-1 expression from CD4+ gated
population. Plots representative of five pooled mice per group.
doi:10.1371/journal.pone.0011453.g006
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or absence of kanamycin (50 mg/mL) and stored in frozen aliquots
at 280uC. For infections, ampoules were thawed, diluted in PBS,
and briefly sonicated to obtain single-cell suspensions. For systemic
infection, a non-lethal dose of 16107 CFU in 100 mL was
intraperitoneally injected. For localized infection, a dose of
1.256106 CFU was injected subcutaneously into the footpads.
Kanamycin-resistant GFP-BCG was generated using an HSP60
promoter driven GFP plasmid, generously provided by Dr. Glen
Fennelly (Albert Einstein University, NY), and dsRED BCG was a
generous gift from Dr. Lalita Ramakrishnan (University of
Washington, WA). Growth and preparation of wild-type BCG
Pasteur strain (Staten Serum Institute, Copenhagen, Denmark)
were performed as previously described [29].
Mononuclear cell isolation
Aseptic isolation of splenocytes and lymph nodes was performed
using standard methods. Granuloma preparations were performed
as previously described [29,80–82]. Briefly, granuloma suspensions
were prepared from freshly excised infected livers. The livers were
homogenized in a Waring tissue blender, and granulomas were
allowed to settle by virtue of their higher density compared to
other hepatic cells. After settling the supernatant was decanted,
and granulomas were washed in RPMI 1640 medium and
centrifuged at 1,500 rpm for 5 minutes. The washed granuloma
pellets were digested with 5 mg/ml type I collagenase (Sigma-
Aldrich, St. Louis, MO) at 37uC for 40 min with shaking. The
softened granulomas were disrupted by repeated expulsion
through a syringe for 1 minute. To remove debris, the suspension
was filtered through a 70 mm nylon cell strainer (BD Bioscience,
San Jose, CA). After lysing red blood cells, cell suspension was
washed twice with RPMI 1640 medium and live leukocyte count
was determined by trypan blue staining. Granuloma suspensions
were obtained by pooling at least 3 or more infected livers per time
point.
Figure 7. Newly activated Ag85B-specific Th1 cells are recruited at similar levels to acute and chronic granulomas, but produce less
IFNc in chronic granulomas. A, Experimental schema. Coinciding three- and ten-week dsRED BCG systemically infected CD11c-EYFP mice received
s.c. footpad injections of 1.256106 CFU GFP BCG seven days prior to harvest. The following day 106 CFSE dsRED Ag85B-specifc transgenic CD4+ T cells
were adoptively transferred via retro-orbital sinus vein injection. Mice were harvested six days later and granuloma cells were isolated. B, Left FACS
panel, Presence of transferred P25 dsRED CD4+ T cells in both three- and ten-week granulomas. CD4+dsRed+ co-staining indicates adoptively
transferred population. Plots derived from lymphocyte gate on SSC vs. FSC. B, Right FACS panel, CFSE dilution of gated P25 dsRED CD4+ T cell
population indicates the recent activation of these T cells. B, Lower panels, Fluorescent microscopy reveals contact between CD11c-EYFP cells (green)
and P25 dsRED CD4+ T cells (red) in granuloma (DAPI-blue). Images taken at 10006magnification. Right images, Enlarged image of small white box.
C, Left FACS panels, ex vivo restimulation of granuloma cells and staining for LFA-1 expression and IFNc production. Plot was obtained from gated
dsRED CD4+ T cell population as shown in B. C, Right graph, Average P25 IFNc production in the granuloma from three independent experiments,
displayed as a percent of total CD4+dsRED/Vb11+ cells in lymphocyte gate (data are represented as mean +/2 SEM). Plots representative of three
independent experiments with 2–7 mice per group. These data show that despite CD4+IFNc-producing mycobacterium-specific T cells reaching both
acute and chronic granulomas, the IFNc response is blocked (not reactivated) in chronic lesions.
doi:10.1371/journal.pone.0011453.g007
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Flow cytometry
A total of 106 cells were incubated for 30 min on ice with
saturating concentrations of labeled Abs with 40 mg/mL
unlabeled 2.4G2 mAb to block binding to Fc receptors and
washed 3 times with staining buffer (PBS plus 1% BSA).
Fluorochrome-labeled Abs against CD11c (HL3), CD11b
(Mac-1), CD4 (RM5-4), LFA-1 (2D7), B220 (RA3-6B2),
MHCII I-Ab (AF6-120.1), CD40 (3/23), CD80 (16-10A1),
CD86 (GL1), IFNc (XMG1.2), IL-2 (JES6-5H4), and Vb11
(RR3-15) were purchased from BD Biosciences (San Jose, CA).
Fluorochrome-labeled Abs against CD8a (53-6.7), PD-L1
(MIH5), and PD-L2 (TY25) were purchased from eBioscience
(San Diego, CA). Anti-CD16/CD32 (2.4G2), anti-CD3 (145–
2C11) and anti-GR-1 (RB6) Abs were produced from
hybridomas. For intracellular cytokine staining, single-cell
suspensions from various tissues were cultured at 37uC in
complete RPMI 1640 supplemented with GolgiStop (BD
Biosciences) in the presence of anti-CD3 Ab for 5 h. After
surface staining with anti-LFA-1 and anti-CD4 Abs, cell
suspensions were fixed and permeabilized by Cytofix/
Cytoperm solution (BD Biosciences), followed by staining with
anti-IFNc and/or IL-2 Ab. Cell surface staining was acquired
on a FACSCalibur or LSRII (BD Biosciences, San Jose, CA)
and analyzed with FlowJo (Tree Star) software version 5.4.5.
Generation of recombinant PD1-Fc construct
PD1-Fc was generated by fusing the extracellular domain of
PD1 to a human IgG1 Fc fragment. PD1 was amplified from
spleen-derived cDNA using oligonucleotides specific for the signal
sequence (EcoR1PD1, atc gaa ttc acc tga gat gtc ttc ttt tgc) and the
membrane proximal region of the extracellular region (hingePD1,
ggc atg tgt gag ttt tgt cac cag att tgg gct caa ctt tgc ctt gaa acc ggc
ctt ctg g). The Fc region of human IgG1 was amplified from the
vector pHC-huIgG1 [83]. PCR products of PD1 and of Fc were
fused by overlap-extension PCR, where the hinge region served as
the overlapping sequence. The fused product was digested by
EcoRI and XhoI and ligated into the pHC-huIgG1 plasmid from
which IgG1 was excised by EcoRI and XhoI. The fusion protein
was purified from supernatant of transfected CHO-K cells using
protein G affinity chromatography.
Figure 8. Naı¨ve CD4+ OTII T cell activation by CD11c+ cells from acute and chronic granulomas. A, Experimental schema. B, CD11c+ cells
from three- and ten-week BCG infected animals were purified and cultured with purified naı¨ve OTII CD4+ T cells at 5:1 ratio of T cell reponders:APCs,
respectively. Cells were co-cultured ex vivo for 48 hours, followed by a five hour recall with anti-CD3. Cells were stained for intracellular cytokines IFNc
(left FACS plots) and IL2 (right FACS plots). B right graph, IFNc ELISA of supernatant following 48 hours ex vivo co-culture. Cells shown were from
CD4+Vb5+ lymphocyte gate. Granuloma cells from 5–8 mice were pooled for each time point.
doi:10.1371/journal.pone.0011453.g008
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OTII stimulation and P25 reactivation by DCs from acute
and chronic granulomas
DCs were isolated from 3- and 10-week granuloma preparations
using a CD11c MicroBeads Cell Separation Kit from Miltenyi
Biotec (Auburn, CA). Live transgenic OTII CD4+ T cells were
sorted using a FACSVantageSE at the University of Wisconsin
Comprehensive Cancer Center’s Flow Facility. Pooled lymph
node CD4+ Ag85b-specific T cells from 3-week BCG infected
were purified using a Dynal Mouse CD4 Negative Isolation Kit
following manufactures protocol (Invitrogen, Carlsbad, CA).
CD4+ T cells (16105) were co-cultured with sorted CD11c+ cells
at a 5:1 ratio of T cells:DCs, respectively. For OTII activation,
cells were cultured in a 96 well plate in complete RPMI in the
presence of 5 mg/mL OVA for 2 days at 37uC with 5% CO2.
Frozen supernatant from 2-day culture was used for IFNc ELISA,
samples ran in quadruplicate. Ready-Set-Go! Mouse Interferon
gamma ELISA kit was used following manufacture’s protocol
(eBioscience, San Diego, CA). For P25 reactivation, sorted DCs
were pre-cultured in a 96 well plate (26104) in complete RPMI
with either media, both isotype controls (Rat IgG2a k and IgG2b
k - eBioscience, San Diego, CA), both anti-PD-L1 (10F.9G2-
BioLegend, San Diego, CA) and anti-PD-L2 (TY25- eBioscience,
Figure 9. Blockade with anti-PD-L1 and anti-PD-L2 mAbs, or PD1-Fc restores 10-week granuloma CD11c+ cells’ ability to
restimulate allogenic CD4+ T cells to produce IFNc. DCs (26104) purified from 3- and 10-week granulomas were cocultured ex vivo with
purified, primed Ag85B-specifc transgenic CD4+ T cells (16105). Intracellular IFNc production was measured four hours after DC pretreatment with
isotype control or anti-PD-L1 and anti-PD-L2 pretreatment (A), and media or PD1-Fc pretreatment (B). FACS lots were derived from initial lymphocyte
gate on SSC vs. FSC, followed by gating of CD4+Vb11+ population. Representative FACs plots are shown from groups of 3–7 mice per group. Data are
represented as mean +/2 SEM.
doi:10.1371/journal.pone.0011453.g009
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San Diego, CA) at 10 ug/mL each, and Fc-PDL at 50 ug/mL for
1 hour prior to addition of T cells. Purified T cells (16105) were
added to each well along with GolgiStop (BD Biosciences) and
0.5 ug/mL P25 peptide (Mtb Ag85B AA240–254, Invitrogen
Carlsbad, CA). After 4 hours at 37uC with 5% CO2 cells were
stained for intracellular cytokine, IFNc, for flow cytometry
analysis.
Fluorescent Microscopy
Organs fixed over night in 3% formalin/25% sucrose in PBS
were frozen down in O.C.T Compound (Tissue-Tek Sakura,
Torrance, CA). 10 mm thick cryosections were cut from O.C.T-
embedded liver tissue samples and fixed for 10 or 30 min in ice-
cold acetone or 4% formalin in PBS, respectively, then washed
three times with PBS and outlined with a Pap pen. Sections were
blocked with 40 mg/mL 2.4G2 Ab in 1% BSA for 30 min.
Sections were then surface stained for two hours at room
temperature in PBS and washed with PBS for 30 minutes.
Sections were mounted using ProLong Gold antifade reagent with
DAPI (Invitrogen, Carlsbad, CA). All images were acquired with a
camera (Optronics Inc., Goleta, CA) mounted on a fluorescence
microscope (Olympus BX41, Leeds Precision Instruments) using a
1006/1.25 oil objective lens for a final magnification of 10006.
PictureFrame software (Optronics Inc.) was used to obtain JPEG
images. The acquired digital images were processed and analyzed
using Photoshop CS software (Adobe Systems).
Adoptive Transfer
Pooled splenocytes and lymphocytes from P25 transgenic mice
were CFSE labeled as previously described [84] (final CFSE
concentration 1 mM; Molecular Probes). 106 Vb11+CD4+ trans-
genic cells were adoptively transferred intravenously via retro-
orbital vein injection into recipient mice.
Statistical Analysis
Results are given as a means SE or means SD. Comparisons
between groups was done using Student t test analysis. Statistical
significance was determined as P values less than .05.
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Figure 10. Changing role of dendritic cells in mycobacterium-induced granulomas over time. Scheme showing the changing phenotype
of granuloma DCs in the transition from acute to chronic infection. Acute lesions contain DCs with high MHCII, and T cell costimulatory molecule
(MHCII, CD40, CD80/86) expression. As the infection becomes chronic, DCs within the granuloma have decreased expression of MHCII, activating
costimulatory molecules, and increased expression of inhibitory molecules PD-L1 and PD-L2. Expression of these inhibitory molecules results in an
inability of local CD11c+ cells to reactivate IFNc-producing CD4+ T cells, and therefore, shielding the granuloma-located bacteria from an important
anti-bacterial factor.
doi:10.1371/journal.pone.0011453.g010
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